Current issues in gastrointestinal stromal tumors: Incidence, molecular biology, and contemporary treatment of localized and advanced disease

Current Opinion in Gastroenterology

Volumn 23, Issue 2, 2007, Pages 149-158

  Raut, Chandrajit P ^a,c   Morgan, Jeffrey A ^b,c   Ashley, Stanley W ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Gastrointestinal stromal tumor; Imatinib; KIT; Sunitinib; Surgery

Indexed keywords

IMATINIB; PLACEBO; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; TYROSINE KINASE RECEPTOR;

ADJUVANT THERAPY; ADVANCED CANCER; ANEMIA; ASPIRATION BIOPSY; BIOPSY; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RISK; CANCER SURGERY; CANCER THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CLASSIFICATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG RESPONSE; ENDOSCOPIC ECHOGRAPHY; FAMILIAL DISEASE; FATIGUE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HAND FOOT SYNDROME; HISTOLOGY; HUMAN; HYPERTENSION; HYPOTHYROIDISM; LAPAROSCOPY; MITOSIS INDEX; MULTIMODALITY CANCER THERAPY; NAUSEA; OPTIMAL DRUG DOSE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR VOLUME; VOMITING;

COMBINED MODALITY THERAPY; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INCIDENCE; PROGNOSIS;

EID: 33846691775     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32802086d0     Document Type: Review

References (85)

1. Crosby JA, Catton CN, Davis A, et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001; 8:50-59.
2. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231:51-58.
3. Lewis JJ, Brennan MF. Soft tissue sarcomas. Curr Probl Surg 1996; 33:817-872.
4. Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol 2000; 15:1293-1301.
5. Miettinen M, Lasota J. Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438:1-12.
6. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33:459-465.
7. Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 2002; 38:S37-S38.
8. Bauer S, Corless CL, Heinrich MC, et al. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother Pharmacol 2003; 51:261-265.
9. Mazur MT, Clark HB. Gastric stromal tumors: reappraisal of histogenesis. Am J Surg Pathol 1983; 7:507-519.
10. Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 2002; 38 (Suppl 5):S39-S51.
11. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279:577-580.
12. Savage DG, Antman KH. Imatinib mesylate: a new oral targeted therapy. N Engl J Med 2002; 346:683-693.
13. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61:8118-8121.
14. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002; 20:1692-1703.
15. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22:3813-3825.
16. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21:4342-4349.
17. De Giorgi U, Verweij J. Imatinib and gastrointestinal stromal tumors: where do we go from here? Mol Cancer Ther 2005; 4:495-501.
18. Emile JF, Theou N, Tabone S, et al. Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. Clin Gastroenterol Hepatol 2004; 2:597-605.
19. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299:708-710.
20. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003; 125:660-667.
21. Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004; 28:889-894.
22. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23:5357-5364. This study is the most definitive analysis of PDGFRA mutations.
23. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era: a population-based study in western Sweden. Cancer 2005; 103:821-829. A population-based study from a province in Sweden provides information on the true incidence of GISTs.
24. Miettinen M, Lasota J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol 2003; 54:3-24.
25. Perez EA, Livingstone AS, Franceschi D, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg 2006; 202:623-629. This is the first evaluation of the incidence of GIST using the SEER database since the identification of KIT mutations.
26. Kindblom LG, Meis-Kindblom JM, Blumming P, et al. Incidence, prevalence, phenotype, and biologic spectrum of gastrointestinal stroma tumors (GIST): a population-based study [abstract]. Ann Oncol 2003; 13:157.
27. Tryggvason G, Gislason HG, Magnusson MK, Jonasson JG. Gastrointestinal stromal tumors in Iceland, 1990-2003: the Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 2005; 117:289-293. A population-based study reviewing all potential cases in Iceland provides information on the true incidence of GISTs.
28. Beghini A, Tibiletti MG, Roversi G, et al. Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer 2001; 92:657-662.
29. Carney JA, Stratakis CA. Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. Am J Med Genet 2002; 108:132-139.
30. Hirota S, Nishida T, Isozaki K, et al. Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. Gastroenterology 2002; 122:1493-1499.
31. Isozaki K, Terris B, Belghiti J, et al. Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am J Pathol 2000; 157:1581-1585.
32. Li FP, Fletcher JA, Heinrich MC, et al. Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Clin Oncol 2005; 23:2735-2743. Additional data on familial cases of GIST are discussed here.
33. Maeyama H, Hidaka E, Ota H, et al. Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 2001; 120:210-215.
34. Nishida T, Hirota S, Taniguchi M, et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 1998; 19: 323-324.
35. Robson ME, Glogowski E, Sommer G, et al. Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. Clin Cancer Res 2004; 10:1250-1254.
36. Shinomura Y, Kinoshita K, Tsutsui S, Hirota S. Pathophysiology, diagnosis, and treatment of gastrointestinal stromal tumors. J Gastroenterol 2005; 40:775-780. This study summarizes GIST tumor biology, and specifically provides a clear summary of familial cases.
37. Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 2006; 30:90-96. This is a thorough analysis of familial GISTs.
38. Zoller ME, Rembeck B, Oden A, et al. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 1997; 79:2125-2131.
39. Takazawa Y, Sakurai S, Sakuma Y, et al. Gastrointestinal stromal tumors of neurofibromatosis type I (von Recklinghausen's disease). Am J Surg Pathol 2005; 29:755-763.
40. Kinoshita K, Hirota S, Isozaki K, et al. Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients. J Pathol 2004; 202:80-85.
41. Emory TS, Sobin LH, Lukes L, et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999; 23:82-87.
42. Demetri GD, Delaney T. NCCN: sarcoma. Cancer Control 2001; 8:94-101.
43. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005; 16:566-578. The consensus statement addresses some of the controversies in GIST management and provides the level of evidence-behind recommendations.
44. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472-480.
45. Gayed I, Vu T, Iyer R, et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004; 45:17-21.
46. Demetri GD, Morgan JA. Gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract. UpToDate; 2005. http://www.utdol.com/utd/content. [Accessed 17 July 2006] This succinct update summarizes some of the latest therapies in GIST and other mesenchymal gastrointestinal tumors.
47. Rader AE, Avery A, Wait CL, et al. Fine-needle aspiration biopsy diagnosis of gastrointestinal stromal tumors using morphology, immunocytochemistry, and mutational analysis of c-kit. Cancer 2001; 93:269-275.
48. Martin J, Poveda A, Llombart-Bosch A, et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 2005; 23:6190-6198. The prognostic value of specific KIT mutations is presented.
49. Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002; 20:3898-3905.
50. Yan H, Marchettini P, Acherman YI, et al. Prognostic assessment of gastrointestinal stromal tumor. Am J Clin Oncol 2003; 26:221-228.
51. Ernst SI, Hubbs AE, Przygodzki RM, et al. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 1998; 78:1633-1636.
52. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999; 154:53-60.
53. Li SQ, O'Leary TJ, Sobin LH, et al. Analysis of KIT mutation and protein expression in fine needle aspirates of gastrointestinal stromal/smooth muscle tumors. Acta Cytol 2000; 44:981-986.
54. Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999; 59:4297-4300.
55. Joensuu H, Fletcher C, Dimitrijevic S, et al. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002; 3:655-664.
56. Scaife CL, Hunt KK, Patel SR, et al. Is there a role for surgery in patients with 'unresectable' cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg 2003; 186:665-669.
57. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol 2002; 10:81-89.
58. Otani Y, Furukawa T, Yoshida M, et al. Operative indications for relatively small (2-5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases. Surgery 2006; 139:484-492. Favorable outcomes after laparoscopic resection of gastric GISTs are presented in this Japanese study.
59. Davila RE, Faigelm DO. GI stromal tumors. Gastrointest Endosc 2003; 58:80-88.
60. Iwahashi M, Takifuji K, Ojima T, et al. Surgical management of small gastrointestinal stromal tumors of the stomach. World J Surg 2006; 30:28-35.
61. Demetri GD, Benjamin R, Blanke CD, et al. NCCN task force report: optimal management of patients with gastrointestinal stromal tumor (GIST): expansion and update of NCCN clinical practice guidelines. J Natl Compr Cancer Netw 2004; 2 (Suppl 1):S1-S26.
62. Otani Y, Kitajima M. Laparoscopic surgery for GIST: too soon to decide. Gastric Cancer 2005; 8:135-136.
63. Besana-Ciani I, Boni L, Dionigi G, et al. Outcome and long term results of surgical resection for gastrointestinal stromal tumors (GIST). Scand J Surg 2003; 92:195-199.
64. Carboni F, Carlini M, Scardamaglia F, et al. Gastrointestinal stromal tumors of the stomach: a ten-year surgical experience. J Exp Clin Cancer Res 2003; 22:379-384.
65. Langer C, Gunawan B, Schuler P, et al. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg 2003; 90:332-339.
66. Pierie JP, Choudry U, Muzikansky A, et al. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001; 136:383-389.
67. Wu PC, Langerman A, Ryan CW, et al. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. Surgery 2003; 134:656-665; discussion 665-666.
68. Samiian L, Weaver M, Velanovich V. Evaluation of gastrointestinal stromal tumors for recurrence rates and patterns of long-term follow-up. Am Surg 2004; 70:187-191; discussion 191-192.
69. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031-1037.
70. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2:561-566.
71. Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96:925-932.
72. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344:1052-1056.
73. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358:1421-1423.
74. Benjamin RS, Rankin C, Fletcher CD, et al. Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results [abstract]. Proc Am Soc Clin Oncol 2003; 22:814a.
75. Rankin C, Von Mehren M, Blanke C, et al. Dose effect of imatinib (IM) in patients with metastatis GIST: Phase III Sarcoma Group Study S0033. Proc Am Soc Clin Oncol 2004; 23:815a.
76. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364:1127-1134.
77. Van Glabbeke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 2005; 23:5795-5804. Data on imatinib resistance are discussed.
78. Le Cesne A, Perol D, Ray-Coquard I, et al. Interruption of imatinib (IM) in GIST patients with advanced disease: updated results of the prospective French Sarcoma Group randomized phase III trial on survival and quality of life. J Clin Oncol 2005; 23:823s. The consequences of imatinib interruption in the treatment of patients with advanced GIST are presented.
79. van der Zwan SM, DeMatteo RP. Gastrointestinal stromal tumor: 5 years later. Cancer 2005; 104:1781-1788. This comprehensive review summarizes some key developments in GIST therapy.
80. Heinrich MC, Shoemaker JS, Corless CL, et al. Correlation of target kinase genotype with clinical activity of imatinib mesylate in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+) [abstract]. Proc Am Soc Clin Oncol 2005; 23:3s.
81. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42:1093-1103. A correlation between KIT mutation and response to imatinib dose is presented.
82. van den Abbeele AD, Badawi RD, Manola J. Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning [abstract]. Proc Am Soc Clin Oncol 2004; 23:198.
83. Janicek M, Boston M, Potter A, et al. Does pattern of metastases and early measurable changes after treatment predict therapy effect in gastrointestinal stromal tumors (GIST) on STI571 (imatinib). Chicago, Illinois: RSNA Scientific Program; 2002. p. 583.
84. Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004; 45:357-365.
85. Choi H, Faria S, Benjamin R, et al. Monitoring treatment effects of STI-571 on gastrointestinal stromal tumors (GIST) with CT and PET: a quantitative analysis. Chicago, Illinois: RSNA Scientific Program; 2002. p. 583.